Pretreatment characteristics of M0 AML patients according to AML1 gene mutations
| . | Overall population . | Presence of AML1 gene mutation . | Absence ofAML1 gene mutation . | P . |
|---|---|---|---|---|
| N | 59 | 16 | 43 | |
| Mean age, y (range) | 62 (15-88) | 65 (29-88) | 56 (15-87) | .1146 |
| Females, % | 34 | 25 | 37 | .48 |
| Mean WBC count, g/L (range) | 52.7 (1.1-309) | 115 (1.4-309) | 30 (1.1-208) | .001 |
| Mean platelet count, giga/L (range) | 91.3 (4-287) | 83 (8-223) | 94 (4-287) | .71 |
| Mean Hb, g/dL (range) | 8.8 (3.4-14.8) | 8.46 (3.9-14.8) | 9 (3.4-14.7) | .27 |
| Mean circulating blasts, % (range) | 67.3 (1-100) | 77 (12-100) | 63.5 (1-100) | .08 |
| Mean marrow blasts, % (range) | 84.4 (36-100) | 91.4 (75-100) | 82 (36-100) | .032 |
| WBC more than 50 g/L, % pts | 35 | 80 | 19 | < .0001 |
| Dysgranulopoiesis, % pts | 22 | 30 | 19 | .437 |
| Dyserythropoiesis, % pts | 16 | 9 | 19 | .65 |
| Dysmegakaryopoiesis, % pts | 5 | 0 | 8 | 1 |
| FLT3 duplication, % pts | 22 | 28 | 23 | 1 |
| IgH orTCR gene rearrangement, % pts | 22 | 58 | 7 | < .0001 |
| Abnormal karyotypes, % | 32.5 | 12.5 | 37.5 | .166 |
| AML1 mutation, % | 27 | — | — | — |
| CD13 expression, % | 85 | 100 | 77 | .0965 |
| CD33 expression, % | 61 | 41 | 70 | .036 |
| CD7 expression, % | 35 | 15 | 40 | .176 |
| CD34 expression, % | 86 | 93 | 83 | .666 |
| DR expression, % | 83 | 100 | 77 | .049 |
| CR achievement in patients treated intensively, % | 62 | 68 | 62.5 | .76 |
| Median CR duration, mo | 12 | 10 | 17.5 | .69 |
| . | Overall population . | Presence of AML1 gene mutation . | Absence ofAML1 gene mutation . | P . |
|---|---|---|---|---|
| N | 59 | 16 | 43 | |
| Mean age, y (range) | 62 (15-88) | 65 (29-88) | 56 (15-87) | .1146 |
| Females, % | 34 | 25 | 37 | .48 |
| Mean WBC count, g/L (range) | 52.7 (1.1-309) | 115 (1.4-309) | 30 (1.1-208) | .001 |
| Mean platelet count, giga/L (range) | 91.3 (4-287) | 83 (8-223) | 94 (4-287) | .71 |
| Mean Hb, g/dL (range) | 8.8 (3.4-14.8) | 8.46 (3.9-14.8) | 9 (3.4-14.7) | .27 |
| Mean circulating blasts, % (range) | 67.3 (1-100) | 77 (12-100) | 63.5 (1-100) | .08 |
| Mean marrow blasts, % (range) | 84.4 (36-100) | 91.4 (75-100) | 82 (36-100) | .032 |
| WBC more than 50 g/L, % pts | 35 | 80 | 19 | < .0001 |
| Dysgranulopoiesis, % pts | 22 | 30 | 19 | .437 |
| Dyserythropoiesis, % pts | 16 | 9 | 19 | .65 |
| Dysmegakaryopoiesis, % pts | 5 | 0 | 8 | 1 |
| FLT3 duplication, % pts | 22 | 28 | 23 | 1 |
| IgH orTCR gene rearrangement, % pts | 22 | 58 | 7 | < .0001 |
| Abnormal karyotypes, % | 32.5 | 12.5 | 37.5 | .166 |
| AML1 mutation, % | 27 | — | — | — |
| CD13 expression, % | 85 | 100 | 77 | .0965 |
| CD33 expression, % | 61 | 41 | 70 | .036 |
| CD7 expression, % | 35 | 15 | 40 | .176 |
| CD34 expression, % | 86 | 93 | 83 | .666 |
| DR expression, % | 83 | 100 | 77 | .049 |
| CR achievement in patients treated intensively, % | 62 | 68 | 62.5 | .76 |
| Median CR duration, mo | 12 | 10 | 17.5 | .69 |
Hb indicates hemoglobin; WBC, white blood cell; pts, patients; —, not applicable.